Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 1;32(4):648-654.
doi: 10.1093/eurpub/ckac039.

The impact of pausing the Oxford-AstraZeneca COVID-19 vaccine on uptake in Europe: a difference-in-differences analysis

Vageesh Jain  1 , Paula Lorgelly  2
Affiliations

The impact of pausing the Oxford-AstraZeneca COVID-19 vaccine on uptake in Europe: a difference-in-differences analysis

Vageesh Jain et al. Eur J Public Health. .

Abstract

Background: Several countries paused their rollouts of the Oxford-AstraZeneca coronavirus disease-19 (COVID-19) vaccine in mid-March 2021 due to concerns about vaccine-induced thrombosis and thrombocytopenia. Many warned that this risked damaging public confidence during a critical period of pandemic response. This study investigated whether the pause in the use of the Oxford-AstraZeneca vaccine had an impact on subsequent vaccine uptake in European countries.

Methods: We used a difference-in-differences approach capitalizing on the fact that some countries halted their rollouts whilst others did not. A longitudinal panel was constructed for European Economic Area countries spanning 15 weeks in early 2021. Media reports were used to identify countries that paused the Oxford-AstraZeneca vaccine and the timing of this. Data on vaccine uptake were available through the European Centre for Disease Control and Prevention COVID-19 Vaccine Tracker. Difference-in-differences linear regression models controlled for key confounders that could influence vaccine uptake, and country and week fixed effects. Further models and robustness checks were performed.

Results: The panel included 28 countries, with 19 in the intervention group and 9 in the control group. Pausing the Oxford-AstraZeneca vaccine was associated with a 0.52% decrease in uptake for the first dose of a COVID-19 vaccine and a 1.49% decrease in the uptake for both doses, comparing countries that paused to those that did not. These estimates are not statistically significant (P = 0.86 and 0.39, respectively). For the Oxford-AstraZeneca vaccine only, the pause was associated with a 0.56% increase in uptake for the first dose and a 0.07% decrease in uptake for both doses. These estimates are also not statistically significant (P = 0.56 and 0.51, respectively). All our findings are robust to sensitivity analyses.

Conclusions: As new COVID-19 vaccines emerge, regulators should be cautious to deviate from usual protocols if further investigation on clinical or epidemiological grounds is warranted.

PubMed Disclaimer

Figures

Figure 1
Figure 1
All vaccines (top) and Oxford-AstraZeneca vaccine (bottom) uptake over time across all included EEA countries
Figure 2
Figure 2
Overall COVID-19 vaccine uptake over time for first dose (left) and both doses (right): countries that paused Oxford-AstraZeneca vaccine vs. those that did not
Figure 3
Figure 3
Oxford-AstraZeneca vaccine uptake over time for first dose (left) and both doses (right): countries that paused Oxford-AstraZeneca vaccine vs. those that did not
See this image and copyright information in PMC

References

    1. Vogel G, Kupferschmidt K.. ‘It's a very special picture.’ Why vaccine safety experts put the brakes on AstraZeneca's COVID-19 vaccine. Science 2021. doi: 10.1126/science.abi5259. Available at https://www.science.org/content/article/it-s-very-special-picture-why-va....
    1. The Guardian. Which European States have Paused AstraZeneca Jabs Due to Clotting Concerns? 2021. Available at: https://www.theguardian.com/society/2021/mar/15/which-european-states-ha... (01 June 2021, date last accessed).
    1. Evening Standard. Finland Suspends Use of AstraZeneca Vaccine Over Blood Clot Concerns. 2021. Available at: https://www.standard.co.uk/news/world/finland-suspends-astrazeneca-vacci... (01 June 2021, date last accessed).
    1. European Medicines Agency. COVID-19 Vaccine AstraZeneca: PRAC Investigating Cases of Thromboembolic Events—Vaccine’s Benefits Currently Still Outweigh Risks—Update. 2021. Available at: https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-prac-inve... (01 June 2021, date last accessed).
    1. UN News. WHO Backs AstraZeneca COVID Vaccine Amid Clotting Concerns; Green Lights Johnson & Johnson Shots. 2021. Available at: https://news.un.org/en/story/2021/03/1087222 (01 June 2021, date last accessed).

MeSH terms

Substances